Skip to main content

Correction to Consolidated Interim Report 1 January – 30 June 2026

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Correction to Consolidated Interim Report 1 January – 30 June 2026
14 August 2026
Announcement no. 10

The previous announcement with the half year report was missing the report. The announcement is re-published, including the report. On 14 August 2026, the Board of Directors and the Executive Board of Pharma Equity Group A/S (“PEG”, “The Company” or the “Group”) considered and approved the interim report for the Group for the period 1 January – 30 June 2026 (“H1 2026 report”), which can be summarized as follows:

The headlines for the period can be summarized as follows

  • Reponex Pharmaceuticals A/S strengthened its patent position with a new European patent covering the treatment of inflammatory bowel disease, including pouchitis
  • The patent application relating to the treatment regime for RNX-051 has entered the national phase in several key markets, including Europe, the USA, Japan, China and India
  • An arbitral award confirmed that PEG has a valid claim relating to the Portinho S.A. receivable, strengthening the legal basis for the Company’s continued recovery efforts
  • The formulation of RNX-051 has been finalised, and production for the planned clinical study has been established in Germany. Enrolment of the first patient is expected in late 2026 or early 2027, subject to the remaining regulatory, operational and financing requirements
  • Enrolment of the first patient in the planned clinical study of RNX-011 is expected to commence in late 2026
  • Discussions with potential licensing partners continue across Reponex’s clinical programmes
  • Reponex is assessing the possibility of conducting clinical trials in India as a potential pathway towards earlier market access and market-specific licensing agreements
  • Reponex continues discussions regarding potential licensing opportunities in Japan and Abu Dhabi in connection with the further clinical development of its programmes, including dialogue with the Japanese regulatory authorities regarding RNX-051
  • The Group strengthened its capital resources through additional convertible instruments and loans and continues to pursue additional financing to support its planned activities
Key Figures    
      
  30-06-2026 30-06-2025 
  TDKK TDKK 
      
 Profit/loss-2.679 -17.610 
 Receivable Portinho S.A.39.332 33.697 
 Cash and cash equivalents29 702 
 Total assets44.163 37.996 
 Equity25.788 15.076 
 Convertible instruments21.163 0 
 Subordinated convertible loans4.415 15.234 
      

  • The result for H1-2026 was DKK -2.7 million (H1-2025: DKK -17.6 million).
  • Equity as of 30 June 2026 is DKK 25.8 million (30. June 2025: DKK 15.1 million)
  • Cash and cash equivalents as of 30 June 2026 are DKK 0.029 million (30 June 2025: DKK 0.702 million)

Outlook for 2026
The Group maintains its financial guidance for 2026 as presented in the Annual Report 2025, with expected revenue in the range of DKK 3.0–8.6 million and negative EBIT in the range of DKK 5.8–11.4 million.

Online presentation of the H1-2025 report
At 15:00 a.m. today, 14 August 2026, CEO Christian Henrik Tange invites you to an online presentation of the H1 2026 report for the period 1 January 2025 – 30 June 2026 and significant events so far in 2026. Registration is free for everyone and can be done via link:
https://www.inderes.dk/videos/pharma-equity-group-praesentation-af-delarsregnskabet-for-h1-2026

Contact person – Investor Relations
Any questions regarding the H1 2026 report can be directed to the Company’s CEO Christian Henrik Tange, by email investor@pharmaequitygroup.com. On the Company’s website www.pharmaequitygroup.com further information and all published company announcements can be found.

Hørsholm 14 August 2026
Christian Vinding Thomsen, Chairman                                                 Christian Henrik Tange CEO

About Pharma Equity Group A/S

Pharma Equity Group (PEG) is a dynamic life sciences investment and development firm listed on the Nasdaq Copenhagen stock exchange. PEG is dedicated to identifying, acquiring, and advancing innovations across pharmaceuticals (Pharma), medical technology (MedTech), and other medical devices, with a strategic focus on early-stage opportunities, particularly those emerging from Scandinavian research institutions. By leveraging strategic capital allocation, robust governance including a dedicated Investment Committee, and an extensive industry network, PEG aims to transform groundbreaking ideas into impactful healthcare solutions and products. The company is committed to building a balanced portfolio that delivers ongoing value creation and supports long-term growth for the benefit of patients, healthcare systems, and its investors.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.